Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine - LARVOL DELTA

Pattern of Immunizations for Patients With Inflammatory Bowel Disease in Primary Care Clinics: A Tertiary Care Center Experience (ACG 2026) - "Vaccination status was reviewed for the following: influenza, pneumococcal disease, hepatitis A, hepatitis B, human papillomavirus (HPV), tetanus/diphtheria/pertussis (Td/Tdap), COVID-19, and shingles (Shingrix)... Among the 328 patients, 212 were female, 115 male, and 1 non-binary. The average age was 51 years (range: 20â89). The majority identified as White or Caucasian (66%) or Black or African American (28%), with 95% identifying as not Hispanic or Latino (Figure 1)."

Clinical • Gastroenterology • Gastrointestinal Disorder • Hepatitis B • Hepatitis C • Hepatology • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Influenza • Novel Coronavirus Disease • Pertussis • Pneumococcal Infections • Preventive care • Respiratory Diseases • Tetanus • Varicella Zoster

Herpes zoster vaccination in inflammatory bowel disease: Evidence, guidelines, and reality. (PubMed, World J Virol) - "The recombinant zoster vaccine (RZV, Shingrix) provides high efficacy, with 65%-90% protection against HZ and a significant decrease in postherpetic neuralgia, along with a safety profile that does not increase IBD flares, even during immunosuppression...RZV is a safe, effective, and cost-efficient method to decrease HZ-associated morbidity in IBD patients. Integrating vaccination proactively into routine IBD management is crucial to close the gap between current evidence and clinical practice."

Journal • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Neuralgia • Pain • Ulcerative Colitis • Varicella Zoster

Vaccine Effectiveness and Safety of Recombinant Zoster Vaccine in Psoriatic Arthritis Patients Aged 18 Years and Older (ACR Convergence 2026) - "Two doses of RZV were effective against HZ in PsA patients without a significantly elevated rate of PsA flares observed following vaccination."

Clinical • Herpes Zoster • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Varicella Zoster

Impact of Multimodal Intervention on Shingrix Vaccination Rate and Herpes Zoster Incidence Among Patients on JAK or IL-6 Inhibitors (ACR Convergence 2026) - No abstract available

Clinical • Herpes Zoster • Varicella Zoster

Recombinant Zoster Vaccine and Clinical Outcomes in Mnsclc Patients Receiving Icis: A Retrospective Analysis (IASLC-WCLC 2026) - "Whether non-mRNA vaccines such as the recombinant zoster vaccine (RZV; Shingrix) produce similar effects remains unknown...Methods : Using the TriNetX Global Collaborative Network (171 healthcare organizations), we identified patients aged ≥59 with mNSCLC receiving ICI therapy (pembrolizumab, nivolumab, atezolizumab, durvalumab, cemiplimab, or ipilimumab)...The parallel findings across mechanistically distinct platforms mRNA and recombinant protein with AS01B adjuvant suggest vaccination-induced immune activation may potentiate ICI efficacy through a class effect. These findings warrant prospective validation."

Clinical data • Retrospective data • Herpes Zoster • Influenza • Non Small Cell Lung Cancer • Pneumococcal Infections • Respiratory Diseases • Solid Tumor

Targeting premature ageing of the immune system in dialysis patients (TTS 2026) - "This study aims to evaluate response to Shingrix and RSV vaccine responses in hemodialysis patients, identify age-associated immunological markers that predict impaired responses... If age-associated immunosenescence and inflammageing are identified as risk factors for vaccine hyporesponsiveness, sirolimus will be investigated as a treatment to improve vaccine responses in a randomized controlled trial."

Clinical • Herpes Zoster • Infectious Disease • Influenza • Renal Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNG

Reactivation of Varicella-Zoster Virus Keratitis after Recombinant Herpes Zoster Vaccination: A Case Report and Literature Review. (PubMed, Case Rep Ophthalmol) - "A 68-year-old woman with a history of trigeminal HZ without prior corneal involvement developed VZV keratitis 2 months after receiving the recombinant HZ vaccine (Shingrix®)...Reactivation of VZV keratitis after HZ vaccination is an uncommon but clinically relevant event. Ocular reactivation may occur even in patients without previous corneal involvement and may lead to chronic complications, supporting the need for close ophthalmologic follow-up in patients with a history of HZ infection."

Journal • Herpes Zoster • Infectious Disease • Keratitis • Ocular Inflammation • Ophthalmology • Varicella Zoster

Herpes Zoster in Aging Patients: Risk Factors and Prevention Strategies. (PubMed, Int J Gen Med) - "However, gaps in prevention remain. Opportunities exist to improve HZ prevention in adults aged ≥50 years, particularly among those with comorbidities, by expanding medical societies' dissemination tactics for vaccination guidelines and recommendations, and empowering specialists to both incorporate risk assessment into routine care and encourage vaccination guideline adherence."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Diabetes • Herpes Zoster • Infectious Disease • Metabolic Disorders • Nephrology • Neuralgia • Pain • Preventive care • Renal Disease • Varicella Zoster

Safety and Immunogenicity of Recombinant Zoster Vaccine for Dialysis and Transplant Recipients (TTS 2026) - P=N/A | "We sought to assess the effect of immunosuppression regimen on immunogenicity of the recombinant zoster vaccine, Shingrix, in solid organ transplant recipients (SOTRs) and patients on hemodialysis...Participants are enrolled in one of five groups: [1] SOTRs receiving tacrolimus, mycophenolate and prednisolone (n=30); [2] SOTRs receiving mTOR-inhibitor, tacrolimus and prednisolone (n=30); [3] SOTRs receiving mTOR-inhibitor, mycophenolate or azathioprine, and prednisolone (n=30); [4] Patients receiving hemodialysis (n=30); [5] healthy controls (n=30)... This trial is the first to evaluate immunogenicity of the recombinant zoster vaccine in SOTRs and hemodialysis patients relative to healthy individuals. The influence of immunosuppression regimen on the formation and longevity of varicella zoster virus-specific antibody and T cell immunity will be assessed, with data extended to 52 weeks. The outcomes of SIR-ZOSTER will inform subsequent studies of immunosuppression..."

Clinical • Herpes Zoster • Infectious Disease • Renal Disease • Solid Organ Transplantation • Transplantation • Varicella Zoster

Comparison of herpes zoster incidence between live-attenuated and recombinant zoster vaccines in kidney transplant recipients (TTS 2026) - "The introduction of the recombinant zoster vaccine (RZV; Shingrix) in South Korea in December 2022 allowed for post-transplant vaccination... The use of RZV for HZ prevention in KTRs may improve patient outcomes by significantly reducing the incidence of post-transplant HZ. Long-term follow-up is warranted to further evaluate the durability of RZV in this immunocompromised population."

Clinical • Herpes Zoster • Transplantation • Varicella Zoster

Real-Time Single-Aggregate Analysis of Vaccine Antigen Stability via Stochastic Electrochemical Blocking. (PubMed, AAPS J) - "Here, we apply stochastic electrochemical blocking to observe aggregation of the glycoprotein E (gE) antigen from the SHINGRIX™ vaccine under different formulation and temperature conditions...Time trial experiments showed that refrigeration (4 °C) consistently reduced aggregate size, whereas 37 °C accelerated aggregation until particles became too large to reach the electrode. Overall, stochastic electrochemical blocking provides a rapid, tangential method for monitoring protein aggregation in vaccine formulations and offers actionable insights into optimizing storage and reconstitution conditions."

Journal

Effectiveness of pharmacist-delivered vaccination recommendations for herpes zoster: a systematic review. (PubMed, Front Public Health) - "Eight evaluated ZVL (Zostavax), whereas only one specifically assessed RZV (Shingrix) series completion. However, the current evidence base remains limited by the predominance of non-randomized studies and substantial risk of bias. Well-designed randomized and quasi-experimental studies are needed to determine the independent effectiveness of pharmacist-delivered vaccination recommendations."

Journal • Review • Herpes Zoster • Varicella Zoster

Safety profile of herpes zoster vaccines in the United States: a descriptive and disproportionality analysis of adverse events reported to the vaccine adverse event reporting system (VAERS), 2017-2024. (PubMed, Front Med (Lausanne)) - "Herpes zoster causes substantial morbidity in older adults, and US herpes zoster vaccination shifted from the live-attenuated Zostavax to the recombinant Shingrix after 2017 We describe the post-marketing adverse-event profile of these vaccines reported to the US Vaccine Adverse Event Reporting System (VAERS) and identify events reported disproportionately for herpes zoster vaccines. Eight years of VAERS data are consistent with the recognized reactogenicity of the recombinant vaccine and the live-vaccine profile of Zostavax; most reported events were transient and non-serious. These hypothesis-generating disproportionality signals require confirmation in active surveillance with denominator data."

Adverse events • Journal • Herpes Zoster • Infectious Disease • Influenza • Pain • Respiratory Diseases • Varicella Zoster

Association Between Herpes Zoster Vaccination and Dementia Risk: A Systematic Review and Meta-Analysis. (PubMed, Vaccines (Basel)) - "HZV was associated with lower dementia risk in observational studies, with directionally consistent quasi-experimental findings. Direct evidence suggested potentially stronger inverse associations for RZV and complete vaccination, but was based on few independent data sources. Substantial heterogeneity and residual confounding preclude causal interpretation, and further prospective or randomized evidence is needed."

Journal • Retrospective data • Review • Alzheimer's Disease • CNS Disorders • Dementia • Herpes Zoster • Varicella Zoster

Accessing robust vaccine coformulation stability by single adjuvant detection on a microelectrode | Poster Board #1089 (ACS-Fall 2026) - "We then present a time-trial comparison of data from current commercial SHINGRIX™ vaccines using dynamic light scattering and stochastic electrochemistry, analyzing the AS01B adjuvant alone and the AS01B adjuvant combined with the glycoprotein E (gE protein). While our method elucidates important properties at the single adjuvant level, our results paint a quantitative kinetic picture of coformulation stability that is currently not achievable by dynamic light scattering."

Clinical

Accessing Robust vaccine coformulation stability by single adjuvant detection on a microelectrode | Poster Board #D03 (ACS-Fall 2026) - "We then present a time-trial comparison of data from current commercial SHINGRIX™ vaccines using dynamic light scattering and stochastic electrochemistry, analyzing the AS01B adjuvant alone and the AS01B adjuvant combined with the glycoprotein E (gE protein). While our method elucidates important properties at the single adjuvant level, our results paint a quantitative kinetic picture of coformulation stability that is currently not achievable by dynamic light scattering."

Clinical

Accessing Robust vaccine coformulation stability by single adjuvant detection on a microelectrode | Poster Board #D03 (ACS-Fall 2026) - "We then present a time-trial comparison of data from current commercial SHINGRIX™ vaccines using dynamic light scattering and stochastic electrochemistry, analyzing the AS01B adjuvant alone and the AS01B adjuvant combined with the glycoprotein E (gE protein). While our method elucidates important properties at the single adjuvant level, our results paint a quantitative kinetic picture of coformulation stability that is currently not achievable by dynamic light scattering."

Clinical

Adult immunization. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus • Varicella Zoster

Effectiveness of the recombinant zoster vaccine in adult patients with multiple sclerosis: A claims-based retrospective cohort study in the United States. (PubMed, Mult Scler) - "RZV demonstrated robust VE, preventing 64%-81% of HZ cases in this MS population predominantly aged 50 years or older."

Journal • Retrospective data • CNS Disorders • Herpes Zoster • Multiple Sclerosis • Varicella Zoster

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age (clinicaltrials.gov) - P1 | N=659 | Terminated | Sponsor: ModernaTX, Inc. | Phase classification: P1/2 ➔ P1 | Trial completion date: Jun 2026 ➔ Dec 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jun 2026 ➔ Dec 2025; The clinical study was terminated prior to the start of Phase 2 following a business decision to discontinue further development of the vaccine.

First-in-human • Phase classification • Trial completion date • Trial primary completion date • Trial termination • Herpes Zoster • Varicella Zoster

Women and Herpes Zoster in the United States: Risk and Prevention Management-A Narrative Review. (PubMed, Womens Health Rep (New Rochelle)) - "Gaps in HZ prevention persist, including in recombinant zoster vaccine uptake and disparities in vaccination uptake by race and ethnicity. Various methods have been proposed that aim to address gaps in prevention, including approaching vaccination outside of the traditional primary care setting and considering the educational and resource needs of women's health providers.Guidelines and resources from the Centers for Disease Control and Prevention and medical societies are among the tools available to primary care providers and specialists in the women's health space, such as obstetricians/gynecologists and oncologists, to support the incorporation of HZ-preventive care into clinicians' practices."

Journal • Gynecologic Cancers • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Obstetrics • Oncology • Pain • Preventive care • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus • Varicella Zoster • Women's Health

Vaccine Responses in Patients With B Cell Malignancies (clinicaltrials.gov) - P4 | N=350 | Recruiting | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: Aug 2026 ➔ Nov 2036 | Trial primary completion date: Aug 2026 ➔ Nov 2036

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Oncology • BCL2

Reduced polyfunctional immune responses to Shingrix vaccine in people living with HIV since birth (AIDS 2026) - "The Shingrix vaccine was highly immunogenic and durable in both study groups. However, adults with perinatally acquired HIV had reduced T cell polyfunctionality over time. Further studies are needed to determine whether this may indicate a need for additional booster doses."

Herpes Zoster • Human Immunodeficiency Virus • Infectious Disease • Varicella Zoster • CD40LG • IL2 • TNFA

Severe disseminated VZV in an immunocompromised host temporally associated with recent recombinant adjuvanted herpes zoster vaccination. (PubMed, IDCases) - "The patient improved under intravenous acyclovir (10 mg/kg every 8 h) with daily local care, followed by extended valaciclovir prophylaxis. Nonetheless, the short latency, immunocompromised status, and concordance with rare reports of early post-vaccination zoster suggest a possible association. This case highlights the importance of reporting to pharmacovigilance systems and differentiating adverse events from vaccine failure, without undermining the overall favorable safety profile of Shingrix in high-risk populations."

Journal • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Lymphoma • Oncology • Pain • Varicella Zoster

Recombinant Zoster Vaccine Uptake in Patients with Noninfectious Ocular Inflammatory Diseases Receiving Immunosuppression. (PubMed, Am J Ophthalmol) - "Adults aged 19-49 years receiving immunosuppressive therapy for NOID demonstrated lower documented recombinant zoster vaccine uptake than older immunosuppressed adults despite current CDC recommendations supporting vaccination in both groups. These findings highlight a potential opportunity for improved vaccine counseling and implementation strategies among younger immunosuppressed adults."

Journal • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Ocular Inflammation • Respiratory Diseases